The importance of the VEGF-load in platelets in cancer patients

R. Salgado1,2, I. Benoy1,2, E. van Marck1, P. Vermeulen1,2 and L. Dirix2

Angiogenesis Group, 1 Department of Pathology, University of Antwerp; 2 Oncologic Centre, St. Augustinus Hospital, Wilrijk, Belgium. (E-mail: Roberto@uia.ua.ac.be)

We read with interest the paper published by Colleoni and colleagues in which they measured pre- and post-treatment, serum and plasma levels of vascular endothelial growth factor (VEGF) and also platelets, in metastatic breast cancer patients [1]. Although they also analysed antitumor activity with methotrexate and cyclophosphamide in a larger number of patients (n = 64), this letter will focus on the patient population with VEGF and platelet measurements (n = 48).

Their finding that serum VEGF levels decrease after therapy is intriguing, especially when compared with the unaltered levels of plasma VEGF and platelets found after therapy for the whole patient population studied.

In a previous study, we measured serum and plasma VEGF levels and interleukin (IL)-6 in the vein draining colorectal tumours (vena mesenterica) [2]. We found that: 1) serum VEGF levels are ~10-fold higher than plasma VEGF, in accordance with previous findings; 2) serum VEGF was not derived from the primary tumour in these patients; 3) IL-6 was consistently produced by the tumours, illustrated by the high IL-6 levels in the vein draining the tumour.

We and others have previously demonstrated that the VEGF-load in platelets accounts for the vast majority of the high serum VEGF levels encountered in patients with advanced cancer. We hypothesised that the higher platelet VEGF load found in cancer patients may be due to a tumour-derived cytokine (IL-6?)-mediated enhancement of VEGF-production in platelet precursors [3, 4]. The importance of a higher VEGF-load in platelets is illustrated by the association between high platelet VEGF-load and fast tumour growth kinetics and worse prognosis in patients with cancer [5, 6].

The findings of Colleoni and colleagues that serum VEGF levels decrease, but not plasma VEGF levels or platelet count, may be partly explained by a diminished platelet VEGF content in these patients. Furthermore, it is tempting to speculate that cyclophosphamide and methotrexate therapy in these patients affected the release of tumour-produced IL-6, herewith accounting for the lower platelet VEGF-load, and thus serum VEGF, without affecting tumour-production and re-lease of plasma VEGF. Analysing and comparing the platelet VEGF load in their respective groups could help to explain the findings of Colleoni and colleagues.

R. Salgado1,2, I. Benoy1,2, E. van Marck1, P. Vermeulen1,2 & L. Dirix2

Angiogenesis Group, 1Department of Pathology, University of Antwerp; 2Oncologic Centre, St. Augustinus Hospital, Wilrijk, Belgium. (E-mail: Roberto@uia.ua.ac.be)

References

1. Colleoni M, Rocca A, Sandri MT et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol 2002; 13: 73–80.[Abstract/Free Full Text]

2. Salgado R, Vermeulen PB, Van Marck E et al. Correspondence re: M. L. George et al., Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer: clinical evidence of platelet scavenging? Clin. Cancer Res., 6: 3147–3152, 2000. Clin Cancer Res 2001; 7: 1481–1483.[Free Full Text]

3. Benoy I, Salgado R, Colpaert C et al. Serum interleukin 6, plasma VEGF, serum VEGF, and VEGF platelet load in breast cancer patients. Clin Breast Cancer 2002; 2: 311–315.[ISI][Medline]

4. Salgado R, Vermeulen PB, Benoy I et al. Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients. Br J Cancer 1999; 80: 892–897.[ISI][Medline]

5. Salgado R, Benoy I, Weytjens R et al. Serum vascular endothelial growth factor load and interleukin-6 in cancer patients—reply. Br J Cancer 2000; 82: 1896.[ISI][Medline]

6. Dirix LY, Salgado R, Weytjens R et al. Plasma fibrin D-dimer levels correlate with tumour volume, progression rate and survival in patients with metastatic breast cancer. Br J Cancer 2002; 86: 389–395.[ISI][Medline]





This Article
Full Text (PDF)
E-letters: Submit a response
Alert me when this article is cited
Alert me when E-letters are posted
Alert me if a correction is posted
Services
Email this article to a friend
Similar articles in this journal
Similar articles in ISI Web of Science
Similar articles in PubMed
Alert me to new issues of the journal
Add to My Personal Archive
Download to citation manager
Search for citing articles in:
ISI Web of Science (1)
Disclaimer
Request Permissions
Google Scholar
Articles by Salgado, R.
Articles by Dirix, L.
PubMed
PubMed Citation
Articles by Salgado, R.
Articles by Dirix, L.